Fiduciary Wealth Partners LLC Acquires 1,670 Shares of Merck & Co., Inc. $MRK

Fiduciary Wealth Partners LLC boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 313.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,203 shares of the company’s stock after acquiring an additional 1,670 shares during the quarter. Fiduciary Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $174,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MRK. Legend Financial Advisors Inc. bought a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $25,000. Barnes Dennig Private Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $27,000. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after buying an additional 221 shares during the period. MorganRosel Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $36,000. Finally, Advantage Trust Co lifted its holdings in shares of Merck & Co., Inc. by 57.1% during the 2nd quarter. Advantage Trust Co now owns 550 shares of the company’s stock valued at $44,000 after buying an additional 200 shares during the period. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Up 0.4%

NYSE:MRK opened at $87.54 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The firm has a market capitalization of $218.65 billion, a price-to-earnings ratio of 13.49, a price-to-earnings-growth ratio of 0.96 and a beta of 0.37. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $106.49. The business has a fifty day moving average price of $84.43 and a 200-day moving average price of $81.56.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on MRK. Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Saturday. Citigroup began coverage on Merck & Co., Inc. in a report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. Morgan Stanley lowered their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Finally, Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.